AZX 100
Alternative Names: AZX100Latest Information Update: 22 Jul 2014
At a glance
- Originator AzERx
- Developer Capstone Therapeutics; OrthoLogic
- Class Amino acids; Muscle relaxants; Peptides
- Mechanism of Action Heat-shock protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Cerebral vasospasm; Pulmonary fibrosis; Scars; Vascular injuries
Most Recent Events
- 26 Mar 2014 AZX 100 is available for licensing as of March 2014 (http://www.capstonethx.com)
- 20 Jan 2012 Discontinued - Phase-II for Scars in USA (Intradermal)
- 20 Jan 2012 Discontinued - Preclinical for Asthma in USA (Parenteral)